Saniona’s spin-out, Scandion Oncology obtains approval for listing at Spotlight Stock Market

PRESS RELEASE

October 1, 2018

Saniona, a leading biotech company within ion-channel research, today announced that the spin-out company Scandion Oncology has been approved for listing at the Spotlight Stock Market. Scandion Oncology plans to raise about 26 MSEK at a pre-money value of 43.7 MSEK in an upcoming initial public offering. The subscription period will take place during the period October 4 - 18, 2018, and the first day of trading at the Spotlight Stock Market is scheduled to be on November 8, 2018.

“We decided to spin-out the SCO-101 asset in 2017 since cancer is outside our focus area. We are very pleased that Scandion Oncology is now raising capital to finance a Phase 2 study with SCO-101 for treatment of patients with chemotherapy resistant metastatic breast cancer. Saniona holds about 46.5 percent of the shares in Scandion Oncology prior to this financing. Therefore, we believe that Scandion Oncology’s development of innovative therapies for chemotherapy resistant cancers will benefit not only cancer patients but also Saniona’s shareholders,” said Jørgen Drejer, CEO of Saniona.

Scandion Oncology was founded in May 2017 and subsequently acquired Saniona’s clinical candidate, SCO-101, which has been evaluated in Phase 1 studies for another indication. In 2015 Saniona granted scientists at the University of Copenhagen rights to test SCO-101 and related compounds in their screening systems. This led to the discovery that certain compounds displayed the potential to overcome chemotherapy resistance by restoring the sensitivity of cancer cells toward standard chemotherapy. The parties filed a patent and formed Scandion Oncology for further development and commercialisation of this discovery. In addition to SCO-101, Scandion acquired a platform comprised of a large series of chemical analogues and associated knowledge.

Additional information of Scandion Oncology and the planned initial public offering can be found at company’s website:

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: , E-mail:

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 02:00 p.m. CEST on October 1, 2018.

About Saniona

Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for orphan indications such as Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona has partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona’s research center is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at

About Scandion Oncology

Scandion Oncology is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the Company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells.

Investor meetings

In connection with the IPO, Scandion Oncology will present the business and future plans at a number of investment events:

Attachment